ACN
34
-4
SHW
52
2
HON
58
-4
FITB
60
-2
BA
36
-2
TXT
60
-9
PAYX
54
3
WY
45
-2
AEE
43
2
UNP
40
-5
BBY
44
-2
AN
52
-2
CMS
60
2
ZION
55
2
SYY
60
3
PDCO
60
2
SRE
49
-3
NSC
42
-8
HPE
14
2
SWN
70
4
ACN
34
-4
SHW
52
2
HON
58
-4
FITB
60
-2
BA
36
-2
TXT
60
-9
PAYX
54
3
WY
45
-2
AEE
43
2
UNP
40
-5
BBY
44
-2
AN
52
-2
CMS
60
2
ZION
55
2
SYY
60
3
PDCO
60
2
SRE
49
-3
NSC
42
-8
HPE
14
2
SWN
70
4
Financhill
Back

Coherus BioSciences 10K Form

Sell
38

CHRS
Coherus BioSciences

Last Price:
1.95
Seasonality Move:
5.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CHRS News And Ratings

See the #1 stock for the next 7 days that we like better than CHRS

CHRS Financial Statistics

Sales & Book Value

Annual Sales: $257.24M
Cash Flow: $-12.97M
Price / Cash Flow: 0
Annual Sales: $-1.72
Price / Book: 0

Profitability

EPS (TTM): -2.60000
Net Income (TTM): $-237.89M
Gross Margin: $98.25M
Return on Equity: 0%
Return on Assets: -46.35%

Coherus BioSciences Earnings Forecast

Key Coherus BioSciences Financial Ratios

  • The Gross Profit Margin over the past 18 years for CHRS is 38.19%.
  • The Selling, General & Administrative Expenses for CHRS have been equal to 74.64% of Gross Profit Margin.
  • The Research & Development expenses have been 42.54% of Revenue.
  • The Interest Expense is -17.04% of Operating Income.
  • The Net Earning history of CHRS is -92.48% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 10 years.

Coherus BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CHRS
CUSIP: 19249H
Website: coherus.com

Debt

Debt-to-Equity Ratio: -2.45
Current Ratio: 1.43
Quick Ratio: 1.14

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 36.97

CHRS Technical Analysis vs Fundamental Analysis

Sell
38
Coherus BioSciences (CHRS) is a Sell

Is Coherus BioSciences a Buy or a Sell?